The Form 4 filing, an SEC report of insider stock trades, was filed on November 12, 2026. It lists November 9, 2026, as the trade date for Amir Weiss, chief accounting officer at Teva Pharmaceutical Industries (TEVA).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-09 |
| Date of Latest Transaction | 2026-11-09 |
| Buy/Sell | sell |
| Transaction Count | 3 |
| Shares Transacted | 17,289 |
| Price | $43.04 |
| Total Transaction Value | $744,049.38 |
| Insider | |
| Ticker Symbol | TEVA |
| Company | TEVA PHARMACEUTICAL INDUSTRIES LTD |
| Insider Name | Weiss Amir |
| Insider Title | Chief Accounting Officer |
| Sector - Industry | Healthcare - Drug Manufacturers - Specialty & Generic |
| Holdings | |
| Total Shares Owned After Transaction | 3,537 |
| Position Size Change | 83.02% |
| Filing | |
| Filing Date | 2026-11-12 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales reported under SEC transaction code S, which identifies a sale. Amir Weiss sold shares in three transactions, all reported in one filing.
What was the average price of the transaction?
The average sale price was $43.04 per share across the three transactions, rounded to the nearest cent. Prices for each separate sale are not available.
How did this transaction affect the insider's holdings?
Amir Weiss sold 17,289 shares and reported owning 3,537 shares afterward. The sales represented 83.02% of the shares he held before the trades.
What's the total transaction value?
The three sales had a total value of $744,049.38, rounded to the nearest cent. That total covers all 17,289 shares sold.
Are there any special circumstances around this transaction?
The available transaction information did not identify a special arrangement. Filing footnotes were not provided, so any added terms or explanations remain unknown. These details do not establish a reason for the sales.
For research purposes only; not investment advice.